Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study

Journal of the National Cancer Institute

Volumn 107, Issue 7, 2015, Pages

  Bryant, Richard J ^a   Sjoberg, Daniel D ^b   Vickers, Andrew J ^b   Robinson, Mary C ^c   Kumar, Rajeev ^a   Marsden, Luke ^a   Davis, Michael ^d   Scardino, Peter T ^b   Donovan, Jenny ^h   Neal, David E ^e   Lilja, Hans ^a,b,f,g   Hamdy, Freddie C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f LUND UNIVERSITY   (Sweden)

^g TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 2; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; TISSUE KALLIKREIN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER GRADING; CONTROLLED STUDY; CRYOPRESERVATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; VALIDATION PROCESS; AGED; AREA UNDER THE CURVE; BLOOD; CHEMISTRY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; LARGE CORE NEEDLE BIOPSY; MIDDLE AGED; PATHOLOGY; PLASMA; PREDICTIVE VALUE; PROCEDURES; PROSPECTIVE STUDY; PROSTATE TUMOR; SERUM; UNITED KINGDOM;

AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; BIOPSY, LARGE-CORE NEEDLE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; GREAT BRITAIN; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM GRADING; PLASMA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERUM; TISSUE KALLIKREINS;

EID: 84939487442     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv095     Document Type: Article

References (31)

1. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 2013;346:f2023.
2. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomized population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-732.
3. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366(11):981-990.
4. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027-2035.
5. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101(19):1325-1329.
6. Klotz L. Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes. 2013;20(3):204-209.
7. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostatespecific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294(1):66-70.
8. Fadare O, Wang S, Mariappan MR. Practice patterns of clinicians following isolated diagnoses of atypical small acinar proliferation on prostate biopsy specimens. Arch Pathol Lab Med. 2004;128(5):557-560.
9. Nurmikko P, Pettersson K, Piironen T, Hugosson J, Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem. 2001;47(8):1415-1423.
10. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med. 2008;6:19.
11. Vickers A, Cronin A, Roobol M, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: An independent replication. J Clin Oncol. 2010;28(15):2493-2498.
12. Benchikh A, Savage C, Cronin A, et al. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: An independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer. 2010;10:635.
13. Gupta A, Roobol MJ, Savage CJ, et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer. 2010;103(5):708-714.
14. Vickers AJ, Gupta A, Savage CJ, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev. 2011;20(2):255-261.
15. Donovan J, Hamdy F, Neal D, et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7(14):1-88.
16. Lane JA, Donovan JL, Davis M, et al. Active monitoring, radical prostatectomy, or radiotherapy for localized prostate cancer: study design and diagnostic and baseline results of the ProtecT randomized phase 3 trial. Lancet Oncol. 2014;15(10):1109-1118.
17. Ulmert D, Becker C, Nilsson JA, et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem. 2006;52(2):235-239.
18. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: A systematic review. J Urol. 2006;175(5):1605-1612.
19. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intentupdate 2013. Eur Urol. 2014;65(1):124-137.
20. Catto JW, Robinson MC, Albertsen PC, et al. Suitability of PSA-detected localized prostate cancers for focal therapy: experience from the ProtecT study. Br J Cancer. 2011;105(7):931-937.
21. Gleason DF. Veterans Administration Cooperative Urological Research Group. Histological grading and staging of prostatic carcinoma. In: TannenbaumM, editor. Urologic pathology. Philadelphia, PA: Lea and Febiger; 1977, 171-198.
22. Oxley J, Simpkin A, Goepel J, et al. Gleason drift in the NIHR ProtecT Study. Histopathology. 2015;66(3):438-446.
23. Piironen T, Pettersson K, Suonpaa M, et al. In vitro stability of free prostatespecific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology. 1996;48(6A Suppl):81-87.
24. Vaisanen V, Peltola MT, Lilja H, Nurmi M, Pettersson K. Intact free prostatespecific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. Anal Chem. 2006;78(22):7809-7815.
25. Mitrunen K, Pettersson K, Piironen T, Bjork T, Lilja H, Lovgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem. 1995;41(8 Pt 1):1115-1120.
26. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics. 1988;44(3):837-845.
27. Vickers AJ, Elkin EB. Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565-574.
28. Vickers AJ, Cronin AM, Aus G, et al. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer. 2010;116(11):2612-2620.
29. Vickers AJ, Cronin AM, Roobol MJ, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res. 2010;16(12):3232-3239.
30. Kawachi MH, Bahnson RR, Barry M, et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw. 2010;8(2):240-262.
31. Williams N, Hughes LJ, Turner EL, et al. Prostate-specific antigen testing rates remain low in UK general practice: A cross-sectional study in six English cities. BJU Int. 2011;108(9):1402-1408.